Pershing Square Inc. (PS)
Live price chart, market sentiment, and community perspectives for Pershing Square Inc. (NYSE: PS).
Live price chart, market sentiment, and community perspectives for Pershing Square Inc. (NYSE: PS).
On our fundamental desk, we are looking closely at the divergence between Citi's $50 target and UBS's $39 neutral call following the April 2026 IPO. While permanent capital supports recurring fees, the $190.3M H1 net loss reported in the 10-Q shows that high employee compensation and profit-sharing are severely dragging down earnings. We advise holding off until cash flow stabilizes.
When evaluating the investment management portfolio during our research deep-dives, candidates need to understand how the core funds—PSH, PSUS, and HHH—deploy a high-growth, large-cap equity strategy focusing on tech, real estate, and recent financial additions. Be prepared to discuss how permanent-capital vehicles scale fee-paying AUM differently from traditional hedge fund structures.
Watching the 50-day MA and current price action around $35.67 to $39.58, the options desk is pricing in notable volatility after the Q2 earnings release. With basic loss per share from continuing operations and unrealized losses on PSUS and HHH weighing on the balance sheet, we are hedging upside risk with disciplined put spreads.
From a risk management standpoint, consolidated total assets of $1.81 billion and equity of $1.41 billion as of June 30, 2026, provide a baseline, but the swing from a $43.4 million net income a year earlier to a $190.3 million loss in H1 2026 requires strict downside parameters. Intangible asset amortization and fair value movements are creating too much earnings noise right now.
Our macro asset allocation notes indicate that while PSUS currently offers a compelling 22% NAV discount that catches the eye of value hunters, the parent company stock itself remains a 'Hold' or neutral play until execution risk on distribution channels is empirically proven over subsequent quarters.
In our quantitative prep sessions, we emphasize dissecting the mechanics of the corporate conversion and IPO completed in April 2026, which left 400 million common shares and 1 Special Voting Share outstanding. Analysts must be fluent in how revenue of $111.7 million for the first six months translates into bottom-line dilution from profit-sharing structures.
Explore plasma cleansing, somatic organ swaps, and BCI.